featured
High-Dose Intravenous Immunoglobulin Co-Treatment Prolongs Time to Treatment Escalation in Patients With Autoimmune Bullous Diseases
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
High-dose intravenous immunoglobulin co-treatment prolongs time-to-treatment escalation in autoimmune bullous diseases: A monocentric retrospective cohort study
J Eur Acad Dermatol Venereol 2023 Aug 18;[EPub Ahead of Print], M Bertlich, I Bertlich, N Plümacher, E Hadaschik, A Enk, JHO HoffmannFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.